Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Yuka Hattori is active.

Publication


Featured researches published by Yuka Hattori.


Free Radical Research | 2014

Histological detection of catalytic ferrous iron with the selective turn-on fluorescent probe RhoNox-1 in a Fenton reaction-based rat renal carcinogenesis model

Takahiro Mukaide; Yuka Hattori; Nobuaki Misawa; Satomi Funahashi; Li Jiang; Tasuku Hirayama; Hideko Nagasawa; Shinya Toyokuni

Abstract Iron overload of a chronic nature has been associated with a wide variety of human diseases, including infection, carcinogenesis, and atherosclerosis. Recently, a highly specific turn-on fluorescent probe (RhoNox-1) specific to labile ferrous iron [Fe(II)], but not to labile ferric iron [Fe(III)], was developed. The evaluation of Fe(II) is more important than Fe(III) in vivo in that Fe(II) is an initiating component of the Fenton reaction. In this study, we applied this probe to frozen sections of an established Fenton reaction-based rat renal carcinogenesis model with an iron chelate, ferric nitrilotriacetate (Fe-NTA), in which catalytic iron induces the Fenton reaction specifically in the renal proximal tubules, presumably after iron reduction. Notably, this probe reacted with Fe(II) but with neither Fe(II)-NTA, Fe(III) nor Fe(III)-NTA in vitro. Prominent red fluorescent color was explicitly observed in and around the lumina of renal proximal tubules 1 h after an intraperitoneal injection of 10–35 mg iron/kg Fe-NTA, which was dose-dependent, according to semiquantitative analysis. The RhoNox-1 signal colocalized with the generation of hydroxyl radicals, as detected by hydroxyphenyl fluorescein (HPF). The results demonstrate the transformation of Fe(III)-NTA to Fe(II) in vivo in the Fe-NTA-induced renal carcinogenesis model. Therefore, this probe would be useful for localizing catalytic Fe(II) in studies using tissues.


Redox biology | 2015

Ovarian endometriosis-associated stromal cells reveal persistently high affinity for iron

Masahiko Mori; Fumiya Ito; Lei Shi; Yue Wang; Chiharu Ishida; Yuka Hattori; Masato Niwa; Tasuku Hirayama; Hideko Nagasawa; Akira Iwase; Fumitaka Kikkawa; Shinya Toyokuni

Ovarian endometriosis is a recognized risk for infertility and epithelial ovarian cancer, presumably due to iron overload resulting from repeated hemorrhage. To find a clue for early detection and prevention of ovarian endometriosis-associated cancer, it is mandatory to evaluate catalytic (labile) ferrous iron (catalytic Fe(II)) and to study iron manipulation in ovarian endometriotic lesions. By the use of tissues from women of ovarian endometriosis as well as endometrial tissue from women with and without endometriosis, we for the first time performed histological analysis and cellular detection of catalytic Fe(II) with a specific fluorescent probe (HMRhoNox-M), and further evaluated iron transport proteins in the human specimens and in co-culture experiments using immortalized human eutopic/ectopic endometrial stromal cells (ESCs) in the presence or absence of epithelial cells (EpCs). The amounts of catalytic Fe(II) were higher in ectopic endometrial stromal cells (ecESCs) than in normal eutopic endometrial stromal cells (n-euESCs) both in the tissues and in the corresponding immortalized ESCs. ecESCs exhibited higher transferrin receptor 1 expression both in vivo and in vitro and lower ferroportin expression in vivo than n-euESCs, leading to sustained iron uptake. In co-culture experiments of ESCs with iron-loaded EpCs, ecESCs received catalytic ferrous iron from EpCs, but n-euESCs did not. These data suggest that ecESC play a protective role for cancer-target epithelial cells by collecting excess iron, and that these characteristics are retained in the immortalized ecESCs.


Free Radical Research | 2015

Maternal molecular hydrogen treatment attenuates lipopolysaccharide-induced rat fetal lung injury

Yuka Hattori; Tomomi Kotani; Hiroyuki Tsuda; Yukio Mano; L. Tu; Hua Li; Shima Hirako; Takafumi Ushida; Kenji Imai; Tomoko Nakano; Yoshiaki Sato; Rika Miki; Seiji Sumigama; Akira Iwase; Shinya Toyokuni; Fumitaka Kikkawa

Abstract Maternal inflammation is associated with spontaneous preterm birth and respiratory impairment among premature infants. Recently, molecular hydrogen (H2) has been reported to have a suppressive effect on oxidative stress and inflammation. The aim of this study was to evaluate the effects of H2 on fetal lung injury caused by maternal inflammation. Cell viability and the production of interleukin-6 (IL-6) and reactive oxygen species (ROS) were examined by treatment with lipopolysaccharide (LPS) contained in ordinal or H2-rich medium (HM) using a human lung epithelial cell line, A549. Pregnant Sprague Dawley rats were divided into three groups: Control, LPS, and HW + LPS groups. Rats were injected with phosphate-buffered saline (Control) or LPS intraperitoneally (LPS) on gestational day 19 and provided H2 water (HW) ad libitum for 24 h before LPS injection (HW + LPS). Fetal lung samples were collected on day 20, and the levels of apoptosis, oxidative damage, IL-6, and vascular endothelial growth factor (VEGF) were evaluated using immunohistochemistry. The number of apoptotic cells, and levels of ROS and IL-6 were significantly increased by LPS treatment, and repressed following cultured with HM in A549 cells. In the rat models, the population positive for cleaved caspase-3, 8-hydroxy-2′-deoxyguanosine, IL-6, and VEGF was significantly increased in the LPS group compared with that observed in the Control group and significantly decreased in the HW + LPS group. In this study, LPS administration induced apoptosis and oxidative damage in fetal lung cells that was ameliorated by maternal H2 intake. Antenatal H2 administration may decrease the pulmonary mobility associated with inflammation in premature infants.


PLOS ONE | 2015

Therapeutic Potential of Stem Cells from Human Exfoliated Deciduous Teeth in Models of Acute Kidney Injury.

Yuka Hattori; Hangsoo Kim; Naotake Tsuboi; Akihito Yamamoto; Shinichi Akiyama; Yiqin Shi; Takayuki Katsuno; Tomoki Kosugi; Minoru Ueda; Seiichi Matsuo; Shoichi Maruyama

Background Acute kidney injury (AKI) is a critical condition associated with high mortality. However, the available treatments for AKI are limited. Stem cells from human exfoliated deciduous teeth (SHED) have recently gained attention as a novel source of stem cells. The purpose of this study was to clarify whether SHED have a therapeutic effect on AKI induced by ischemia-reperfusion injury. Methods The left renal artery and vein of the mice were clamped for 20 min to induce ischemia. SHED, bone marrow derived mesenchymal stem cells (BMMSC) or phosphate-buffered saline (control) were administered into the subrenal capsule. To confirm the potency of SHED in vitro, H2O2 stimulation assays and scratch assays were performed. Results The serum creatinine and blood urea nitrogen levels of the SHED group were significantly lower than those of the control group, while BMMSC showed no therapeutic effect. Infiltration of macrophages and neutrophils in the kidney was significantly attenuated in mice treated with SHED. Cytokine levels (MIP-2, IL-1β, and MCP-1) in mice kidneys were significantly reduced in the SHED group. In in vitro experiments, SHED significantly decreased MCP-1 secretion in tubular epithelial cells (TEC) stimulated with H2O2. In addition, SHED promoted wound healing in the scratch assays, which was blunted by anti-HGF antibodies. Discussion SHED attenuated the levels of inflammatory cytokines and improved kidney function in AKI induced by IRI. SHED secreted factors reduced MCP-1 and increased HGF expression, which promoted wound healing. These results suggest that SHED might provide a novel stem cell resource, which can be applied for the treatment of ischemic kidney injury.


Nagoya Journal of Medical Science | 2016

Clinical characteristics of primary peritoneal carcinoma patients : a single-institution experience involving 8 patients

Satomi Hattori; Hiroaki Kajiyama; Utako Fuji; Yuko Furui; Yuki Ishibashi; Yuka Hattori; Noriko Takahashi; Fumitaka Kikkawa; Toshiya Misawa

ABSTRACT Primary peritoneal carcinoma (PPC) is treated similarly to advanced epithelial ovarian carcinoma (aEOC); however, the standard approach for the management of PPC is controversial. The objective of this study was to evaluate the clinical features and prognosis of those patients. A retrospective analysis was performed of eight patients with PPC between January 2008 and December 2015. Clinicopathologic parameters, the diagnostic modality, treatment, and oncologic outcome were analyzed. The median age at the time of diagnosis was 72.5 years (range: 55–79), with a median follow-up of 26.5 months (range, 5–74). Most of the PPC developed with carcinomatosis peritonei involving ascites, while some cases developed sporadically in the peritoneal or extraperitoneal cavity without ascites. The most common initial symptom was abdominal fullness, and other symptoms were inguinal tumor, paralysis of the extremities, and respiratory disorder. The preoperative CA125 value was elevated in all patients. In four patients who did not undergo primary surgery, the final diagnoses were determined by the ascites cytology and radiological image. Initial or interval debulking surgery was performed in only two patients. All patients were treated with paclitaxel or docetaxel plus carboplatin. Five showed a complete response (CR), and one showed a partial response (PR). Among the five patients with CR, the median progression-free and overall survival periods were 15 (12–26) and 41.5 (32–74) months, respectively. Three patients without carcinomatosis peritonei showed a relatively favorable prognosis. The management of PPC is generally consistent with that of aEOC; however, in atypical cases, the treatment method should be considered individually.


Journal of Clinical Biochemistry and Nutrition | 2015

Catalytic ferrous iron in amniotic fluid as a predictive marker of human maternal-fetal disorders

Yuka Hattori; Takahiro Mukaide; Li Jiang; Tomomi Kotani; Hiroyuki Tsuda; Yukio Mano; Seiji Sumigama; Tasuku Hirayama; Hideko Nagasawa; Fumitaka Kikkawa; Shinya Toyokuni


Journal of Clinical Biochemistry and Nutrition | 2016

Pain-reducing anesthesia prevents oxidative stress in human term placenta

Yoko Tsuzuki; Yoriko Yamashita; Yuka Hattori; Guang Hua Li; Shinya Akatsuka; Tomomi Kotani; Fumitaka Kikkawa; Aya Naiki-Ito; Satoru Takahashi; Kimitoshi Nishiwaki; Shinya Toyokuni


Nephrology Dialysis Transplantation | 2015

FP176THERAPEUTIC POTENTIAL OF STEM CELLS FROM HUMAN EXFOLIATED DECIDUOUS TEETH IN MODELS OF ACUTE KIDNEY INJURY

Yuka Hattori; Kim Hangsoo; Naotake Tsuboi; Akihito Yamamoto; Seiichi Matsuo; Shoichi Maruyama


日本産科婦人科學會雜誌 | 2014

ISP-9-1 Therapeutic effect of maternal molecular hydrogen administration in a mouse model of recurrent abortion(Group 9 Perinatology 1,IS Poster,International Session)

Takafumi Ushida; Tomomi Kotani; Yukio Mano; Kenji Imai; Tomoko Nakano; Yuka Hattori; Hiroyuki Tsuda; Seiji Sumigama; Fumitaka Kikkawa


Placenta | 2014

Free ferrous iron in amniotic fluid as a predictive marker of fetal disorders in pregnancy

Yuka Hattori; Tomomi Kotani; Tomoko Nakano; Yukio Mano; Seiji Sumigama; Hiroyuki Tsuda; Takafumi Usida; Hideko Nagasawa; Shinya Toyokuni; Fumitaka Kikkawa

Collaboration


Dive into the Yuka Hattori's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Hideko Nagasawa

Gifu Pharmaceutical University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge